Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Publication: Amylyx Pharmaceuticals, Inc. | Publication Date: April 13, 2023
Authors: Amylyx Pharmaceuticals, Inc.
Significance
Recently published preclinical data demonstrate initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in Wolfram syndrome